Clinical Trial Update: Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

This document reports a Phase 2 clinical trial evaluating loncastuximab tesirine in combination with rituximab for relapsed or refractory follicular lymphoma, c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Zynlonta (loncastuximab tesirine)

Snippet

Sponsor: Juan P. Alderuccio, MD | Conditions: Follicular Lymphoma | Phase 2 | Status: RECRUITING